UIC-2012-013 – Pharmaceutical Compositions for Sleep Disorders

UIC researchers propose pharmacologic compositions with demonstrated efficacy in two human pilot studies. Exemplary embodiments consist of a combination regimen of ondansetron (24 mg/day) and fluoxetine (10 mg/day). Both clinical studies evidence a significant improvement of patient apnea–hypopnea index (AHI) over baseline severity. Neither studies observed a significant difference in adverse events from drug treatment. Moreover, this combination was also paired with a Mandibular Advancement Device (MAD) in the 2017 clinical study to good effect. The golden-standard for OSA treatment is airway pressure devices such as the CPAP. However, the success of airway pressure devices is highly dependent on adherence, which is historically low. Other treatments include lifestyle changes, oral appliances, and surgery. The sleep apnea devices market, which dominates the OSA treatment market, will reach 6 billion USD in 2019 with a CAGR of 7.8%. Nelson Grihalde grihalde@otm.uic.edu 312-996-4129

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More